Why the study?
Cannabidiol exerts anti-inflammatory effects across disease models, but its effects on myocardial dysfunction, oxidative/nitrative stress, and inflammatory signaling pathways in diabetic cardiomyopathy required investigation.
Does cannabidiol attenuate cardiac dysfunction and adverse signaling pathways in preclinical models of diabetic cardiomyopathy?
Population
Mouse model of type I diabetic cardiomyopathy and primary human cardiomyocytes exposed to high glucose
Comparison
Cannabidiol (CBD) treatment
Design
Preclinical animal and in vitro study
Authors
Loading...
Should not change clinical practice in diabetic cardiomyopathy; leaves open CBD's therapeutic potential pending human trials.
Does cannabidiol attenuate cardiac dysfunction and adverse signaling pathways in preclinical models of diabetic cardiomyopathy?
Cannabidiol demonstrates cardioprotective effects in preclinical models of diabetic cardiomyopathy by attenuating oxidative stress, inflammation, cell death, and fibrosis.
Rajesh et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: